Comparison of international working group criteria and national institute on aging-alzheimer's association criteria for alzheimer's disease

Alzheimer's and Dementia

Volumn 8, Issue 6, 2012, Pages 560-563

  Visser, Pieter Jelle ^a,b   Vos, Stephanie ^a   Van Rossum, Ineke ^b   Scheltens, Philip ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer's disease; Biomarkers; Diagnosis; MCI; Neuropsychology

Indexed keywords

BIOLOGICAL MARKER;

AGING; ALZHEIMER DISEASE; CEREBROSPINAL FLUID ANALYSIS; COGNITION; DISEASE CLASSIFICATION; HEALTH CARE ORGANIZATION; HUMAN; MILD COGNITIVE IMPAIRMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

EID: 84867886105     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2011.10.008     Document Type: Note

References (20)

1. B. Dubois, H.H. Feldman, C. Jacova, S.T. Dekosky, P. Barberger-Gateau, and J. Cummings Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria Lancet Neurol 6 2007 734 746
2. M.S. Albert, S.T. DeKosky, D. Dickson, B. Dubois, H.H. Feldman, and N.C. Fox The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging and Alzheimer's Association workgroup Alzheimers Dement 7 2011 270 279
3. G.M. McKhann, D.S. Knopman, H. Chertkow, B.T. Hyman, C.R. Jack, and C.H. Kawas The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup Alzheimers Dement 7 2011 263 269
4. R.A. Sperling, P.S. Aisen, L.A. Beckett, D.A. Bennett, S. Craft, and A.M. Fagan Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup Alzheimer Dement 7 2011 280 292
5. B. Dubois, H.H. Feldman, C. Jacova, J.L. Cummings, S.T. Dekosky, and P. Barberger-Gateau Revising the definition of Alzheimer's disease: a new lexicon Lancet Neurol 9 2010 1118 1127
6. B. Winblad, K. Palmer, M. Kivipelto, V. Jelic, L. Fratiglioni, and L.O. Wahlund Mild cognitive impairment - beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment J Intern Med 256 2004 240 246
7. R.C. Petersen Mild cognitive impairment as a diagnostic entity J Intern Med 256 2004 183 194
8. P.J. Visser, F. Verhey, D.L. Knol, P. Scheltens, L.O. Wahlund, and Y. Freund-Levi Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study Lancet Neurol 8 2009 619 627
9. J.A. Schneider, Z. Arvanitakis, S.E. Leurgans, and D.A. Bennett The neuropathology of probable Alzheimer disease and mild cognitive impairment Ann Neurol 66 2009 200 208
10. C.R. Jack Jr., D.S. Knopman, W.J. Jagust, L.M. Shaw, P.S. Aisen, and M.W. Weiner Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade Lancet Neurol 9 2010 119 128
11. S. Vos, H. Soininen, P.J. Visser, K. Blennow, F. Verhey, and L. Burns CSF and MRI biomarkers as predictors for Alzheimer's-type dementia in subjects with mild cognitive impairment Alzheimers Dement 7 2011 S105
12. A multicenter, double blind, placebo-controlled, safety and tolerability study of BMS-708163 in patients with prodromal Alzheimer's disease. Available at: http://clinicaltrials.gov/ct2/show/NCT00890890. Accessed July 23, 2011.
13. A study of gantenerumab in patients with prodromal Alzheimer's disease. Available at: http://clinicaltrials.gov/ct2/show/NCT01224106. Accessed July 23, 2011.
14. I.A. van Rossum, P.J. Visser, W. van der Flier, M.A. Blankenstein, and P. Scheltens Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease J Alzheimers Dis 29 2012 319 327
15. C.R. Jack, H.J. Wiste, P. Vemuri, S.D. Weigand, M.L. Senjem, and G. Zeng Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease Brain 133 2010 3336 3348
16. O. Hansson, P. Buchhave, H. Zetterberg, K. Blennow, L. Minthon, and S. Warkentin Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease Neurobiol Aging 30 2009 165 173
17. A.K. Wallin, K. Blennow, H. Zetterberg, E. Londos, L. Minthon, and O. Hansson CSF biomarkers predict a more malignant outcome in Alzheimer disease Neurology 74 2010 1531 1537
18. M.I. Kester, A.E. van der Vlies, M.A. Blankenstein, Y.A. Pijnenburg, E.J. van Elk, and P. Scheltens CSF biomarkers predict rate of cognitive decline in Alzheimer disease Neurology 73 2009 1353 1358
19. H. Engler, A.F. Santillo, S.X. Wang, M. Lindau, I. Savitcheva, and A. Nordberg In vivo amyloid imaging with PET in frontotemporal dementia Eur J Nucl Med Mol Imaging 35 2008 100 106
20. C. Porteri, S. Galluzzi, C. Geroldi, and G.B. Frisoni Diagnosis disclosure of prodromal Alzheimer disease - ethical analysis of two cases Can J Neurol Sci 37 2010 67 75